Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity

Loes F. M. van der Zanden, Sita H. Vermeulen, Arna Oskarsdottir, Jake S. F. Maurits, Meta H. M. Diekstra, Valentin Ambert, Anne Cambon-Thomsen, Daniel Castellano, Achim Fritsch, Jesus Garcia Donas, Rosa Guarch Troyas, Henk-Jan Guchelaar, Arndt Hartmann, Christina Hulsbergen-van de Kaa, Ulrich Jaehde, Kerstin Junker, Anna Martinez-Cardus, Gisli Masson, Jeannette Oosterwijk-Wakka, Marius T. RaduThorunn Rafnar, Cristina Rodriguez-Antona, Max Roessler, Rob Ruijtenbeek, Kari Stefansson, Anne Warren, Lodewyk Wessels, Tim Eisen, Lambertus A. L. M. Kiemeney*, Egbert Oosterwijk

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)


Objective: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort.

Methods and materials: EuroTARGET is a European collaborative project designed as an observational study for which patients with mRCC were recruited prospectively in 62 centers. In addition, 462 patients with mRCC from previous studies were included. Detailed clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor DNA, RNA, kinome, and methylome analyses.

Results: In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted treatment (sunitinib [N = 713, 78%], sorafenib [N = 41, 4%], or pazopanib [N = 166, 18%]) and had at least 6 months of outcome assessment (median follow-up 15.3 months [interquartile range: 8.5-30.2 months]). Germline DNA samples were available from 824 of these patients, fresh-frozen tumor material from 142 patients, fresh-frozen normal kidney tissue from 95 patients, and tissue microarrays created from formalin-fixed paraffin-embedded tumor material from 247 patients. Of the 920 patients, germline DNA variant chip data were successfully generated for 811 patients (Illumina HumanOmniExpress BeadChip). For 80 patients, next-generation exome sequencing of germline and tumor DNA was performed, tumor RNA sequencing was performed for 124 patients, kinome activity measured and processed for 121 patients (PamChip), and methylome data (Illumina Infinium HumanMethylation450 BeadChip) were created for 116 RCC tissues (and 23 normal kidney tissues). For 73 out of the 920 patients, all platform data types were generated. In addition, 40 patients were included in a pharmacokinetic/pharmacodynamic phase IV substudy.

Conclusions: Analysis of EuroTARGET cohort data will contribute to personalization of therapy for patients with mRCC. The extensive clinical data and multiplatform EuroTARGET data will be freely available. (C) 2017 The Authors. Published by Elsevier Inc.

Original languageEnglish
Article numberARTN 529.e9
Number of pages8
JournalUrologic oncology-seminars and Original Investigations
Issue number8
Publication statusPublished - Aug 2017


  • Metastatic renal cell carcinoma
  • Therapy response
  • Tyrosine kinase inhibitor
  • Biomarker
  • Transcriptomics
  • Genomics

Cite this